A Director at Sangamo Biosciences (NASDAQ: SGMO) is Buying Shares

By Carrie Williams

Yesterday, a Director at Sangamo Biosciences (SGMOResearch Report), Stewart Parker, bought shares of SGMO for $15.57K.

Following this transaction Stewart Parker’s holding in the company was increased by 30% to a total of $72.28K. In addition to Stewart Parker, 2 other SGMO executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Sangamo Biosciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $54.85 million and quarterly net profit of $4.56 million. In comparison, last year the company earned revenue of $26.84 million and had a GAAP net loss of $18.66 million. The company has a one-year high of $13.91 and a one-year low of $4.81.

The insider sentiment on Sangamo Biosciences has been positive according to 26 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.